A
Angela DeMichele
Researcher at University of Pennsylvania
Publications - 368
Citations - 19335
Angela DeMichele is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 63, co-authored 303 publications receiving 14810 citations. Previous affiliations of Angela DeMichele include University of Rochester Medical Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli,Nicholas C. Turner,Igor Bondarenko,Jungsil Ro,Seock-Ah Im,Norikazu Masuda,Marco Colleoni,Angela DeMichele,Sherene Loi,Sunil Verma,Hiroji Iwata,Nadia Harbeck,Ke Zhang,Kathy Puyana Theall,Yuqiu Jiang,Cynthia Huang Bartlett,Maria Koehler,Dennis J. Slamon +17 more
TL;DR: This study aimed to confirm the earlier findings with this extended follow-up and show the results for subgroup and biomarker analyses, and assesses endocrine therapy resistance by clinical parameters, quantitative hormone-receptor expression, and tumour PIK3CA mutational status in circulating DNA at baseline.
Journal ArticleDOI
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Nicholas C. Turner,Dennis J. Slamon,Jungsil Ro,Igor Bondarenko,Seock-Ah Im,Norikazu Masuda,Marco Colleoni,Angela DeMichele,Sherene Loi,Sunil Verma,H. Iwata,Nadia Harbeck,Sibylle Loibl,Fabrice Andre,Kathy Puyana Theall,Xin Huang,Carla Giorgetti,Cynthia Huang Bartlett,Massimo Cristofanilli +18 more
TL;DR: Treating patients with hormone‐receptor–positive, HER2‐negative advanced breast cancer who had sensitivity to previous endocrine therapy with palbociclib plus fulvestrant resulted in longer overall survival than treatment with placebo–fulvestrant; the efficacy of subsequent therapies after disease progression; and safety.
Journal ArticleDOI
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis,Lajos Pusztai,Vicente Valero,Daniel J. Booser,Laura J. Esserman,Ana Lluch,Tatiana Vidaurre,Frankie A. Holmes,Eduardo A. Souchon,Hongkun Wang,Miguel Martin,Jose M. Cotrina,Henry L. Gomez,Rebekah Hubbard,J. Ignacio Chacón,Jaime Ferrer-Lozano,Richard Dyer,Meredith Buxton,Yun Gong,Yun Wu,Nuhad K. Ibrahim,Eleni Andreopoulou,Naoto T. Ueno,Kelly K. Hunt,Wei Yang,Arlene Nazario,Angela DeMichele,Joyce O'Shaughnessy,Gabriel N. Hortobagyi,W. Fraser Symmans +29 more
TL;DR: A genomic predictor combining ER status, predicted Chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy.
Journal ArticleDOI
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
Lin Zhang,Stefano Volinia,Tomas Bonome,George A. Calin,Joel Greshock,Joel Greshock,Nuo Yang,Chang Gong Liu,Antonis Giannakakis,Antonis Giannakakis,Pangiotis Alexiou,Kosei Hasegawa,Cameron N. Johnstone,Molly Megraw,Sarah Adams,Heini Lassus,Jia Huang,Sippy Kaur,Shun Liang,Praveen Sethupathy,Arto Leminen,Victor A. Simossis,Raphael Sandaltzopoulos,Yoshio Naomoto,Dionyssios Katsaros,Phyllis A. Gimotty,Angela DeMichele,Qihong Huang,Ralf Bützow,Anil K. Rustgi,Barbara L. Weber,Barbara L. Weber,Michael J. Birrer,Artemis G. Hatzigeorgiou,Carlo M. Croce,George Coukos +35 more
TL;DR: The results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer.
Journal ArticleDOI
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Hope S. Rugo,Olufunmilayo I. Olopade,Angela DeMichele,Christina Yau,Laura J. van't Veer,Meredith Buxton,Michael Hogarth,Nola M. Hylton,Melissa Paoloni,Jane Perlmutter,W. Fraser Symmans,Douglas Yee,A. Jo Chien,Anne M. Wallace,Henry G. Kaplan,Judy C. Boughey,Tufia C. Haddad,Kathy S. Albain,Minetta C. Liu,Claudine Isaacs,Qamar J. Khan,Julie E. Lang,Rebecca K. Viscusi,Lajos Pusztai,Stacy L. Moulder,Stephen Y. Chui,Kathleen Kemmer,Anthony D. Elias,Kirsten K. Edmiston,David M. Euhus,Barbara Haley,Rita Nanda,Donald W. Northfelt,Debasish Tripathy,William C. Wood,Cheryl Ewing,Richard Schwab,Julia Lyandres,Sarah E. Davis,Gillian L. Hirst,Ashish Sanil,Donald A. Berry,Laura J. Esserman +42 more
TL;DR: The process used in the I-SPY 2 trial showed that veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone specifically in triple-negative breast cancer.